Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype, Clin J Am Soc Nephrol, vol.5, pp.1844-1859, 2010. ,
Mutations in alternative pathway complement proteins in American patients with atypical hemolytic uremic syndrome, Hum Mutat, vol.31, pp.1445-1460, 2010. ,
Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults, Clin J Am Soc Nephrol, vol.8, pp.554-562, 2013. ,
Atypical hemolytic uremic syndrome, Semin Nephrol, vol.33, pp.508-530, 2013. ,
URL : https://hal.archives-ouvertes.fr/hal-01793663
Atypical hemolytic uremic syndrome: what is it, how is it diagnosed, and how is it treated?, Hematology, vol.2012, pp.617-625, 2012. ,
An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document, Nefrologia, vol.33, pp.27-45, 2013. ,
How I treat: the clinical differentiation and initial treatment of adult patients with atypical hemolytic uremic syndrome, Blood, vol.123, pp.2478-2484, 2014. ,
How I treat thrombotic thrombocytopenic purpura and atypical haemolytic uraemic syndrome, Br J Haematol, vol.164, pp.759-766, 2014. ,
Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome, Nat Genet, vol.45, pp.531-536, 2013. ,
URL : https://hal.archives-ouvertes.fr/hal-01064383
European Paediatric Study Group for HUS (2009) Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome, Pediatr Nephrol, vol.24, pp.687-696 ,
An audit analysis of a guideline for the investigation and initial therapy of diarrhea negative (atypical) hemolytic uremic syndrome, Pediatr Nephrol, vol.29, pp.1967-1978, 2014. ,
Group for aHUS/C3G (2012) Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies, Nat Rev Nephrol, vol.8, pp.643-657 ,
Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome, N Engl J Med, vol.368, pp.2169-2181, 2013. ,
Complement therapy in atypical haemolytic uraemic syndrome (aHUS), Mol Immunol, vol.56, pp.199-212, 2013. ,
European Paediatric Research Group for HUS (2006) A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disorders, Kidney Int, vol.70, pp.423-431 ,
Atypical hemolytic uremic syndrome, Orphanet J Rare Dis, vol.6, p.60, 2011. ,
URL : https://hal.archives-ouvertes.fr/inserm-02157634
Factor H, membrane cofactor protein, and factor I mutations in patients with hemolysis, elevated liver enzymes, and low platelet count syndrome, Blood, vol.112, pp.4542-4545, 2008. ,
Complement mutationassociated de novo thrombotic microangiopathy following kidney transplantation, Am J Transplant, vol.8, pp.1694-1701, 2008. ,
Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations, J Am Soc Nephrol, vol.21, pp.859-867, 2010. ,
URL : https://hal.archives-ouvertes.fr/hal-00512540
Update on Streptococcus pneumoniae associated hemolytic uremic syndrome, Curr Opin Pediatr, vol.25, pp.203-208, 2013. ,
Paradigm shift of childhood thrombotic thrombocytopenic purpura with severe ADAM TS13 deficiency, Presse Med, vol.41, pp.137-155, 2012. ,
Thrombotic thrombocytopenic purpura in children, Curr Opin Pediatr, vol.25, pp.216-224, 2013. ,
Inherited thrombotic thrombocytopenic purpura in children, Semin Thromb Hemost, vol.40, pp.487-492, 2014. ,
Children and adults with thrombotic thrombocytopenic purpura associated with severe, acquired Adamts13 deficiency: comparison of incidence, demographic and clinical features, Pediatr Blood Cancer, vol.60, pp.1676-1682, 2013. ,
Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura, Thrombotic Microangiopathies Reference Centre, vol.124, pp.204-210, 2014. ,
Surveillance of hemolytic uremic syndrome in children less than 15 years of age, a system to monitor O157 and non-O157 Shiga toxin-producing Escherichia coli infections in France, Pediatr Infect Dis J, vol.27, pp.595-601, 1996. ,
Need for long-term follow-up in enterohemorrhagic Escherichia coli-associated hemolytic uremic syndrome due to late-emerging sequelae, Clin Infect Dis, vol.54, pp.1413-1421, 2012. ,
Longterm outcomes of Shiga toxin hemolytic uremic syndrome, Pediatr Nephrol, vol.28, pp.2097-2105, 2013. ,
Hemolytic uremic syndrome (HUS) secondary to cobalamin C (cblC) disorder, Pediatr Nephrol, vol.22, pp.2097-2103, 2007. ,
Neonatal atypical hemolytic uremic syndrome due to methylmalonic aciduria and homocystinuria, Pediatr Nephrol, vol.27, pp.1401-1405, 2012. ,
Adult-onset eculizumab-resistant hemolytic uremic syndrome associated with cobalamin C deficiency, Am J Kidney Dis, vol.63, pp.119-123, 2013. ,
URL : https://hal.archives-ouvertes.fr/hal-01011789
Combined pulmonary hypertension and renal thrombotic microangiopathy in cobalamin C deficiency, Pediatrics, vol.132, pp.540-544, 2013. ,
Clinical presentation and outcome in a series of 88 patients with the cblC defect, J Inherit Metab Dis, vol.37, pp.831-840, 2014. ,
Three new cases of late-onset cblC defect and review of the literature illustrating when to consider inborn errors of metabolism beyond infancy, Orphanet J Rare Dis, vol.9, p.161, 2014. ,
Successful use of eculizumab in a patient with post-transplant thrombotic microangiopathy, Br J Haematol, vol.161, pp.279-280, 2013. ,
Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy, Blood, vol.122, pp.2003-2007, 2013. ,
Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy, Biol Blood Marrow Transplant, vol.20, pp.518-525, 2014. ,
The role of complement in Streptococcus pneumoniae-associated haemolytic uraemic syndrome, Nephrol Dial Transplant, vol.28, pp.2237-2245, 2013. ,
Does dysregulated complement activation contribute to haemolytic uraemic syndrome secondary to Streptococcus pneumoniae?, Med Hypotheses, vol.81, pp.400-403, 2013. ,
FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay, Br J Haematol, vol.129, pp.93-100, 2005. ,
Discrepancies between ADAMTS13 activity assays in patients with thrombotic microangiopathies, Thromb Haemost, vol.109, pp.488-496, 2013. ,
Evaluation of a commercial assay for ADAMTS13 activity measurement, Thromb Haemost, vol.110, pp.852-853, 2013. ,
International Registry of Recurrent and Familial HUS/TTP (2005) Complement factor H mutation in familial thrombotic thrombocytopenic purpura with ADAMTS13 deficiency and renal involvement, J Am Soc Nephrol, vol.16, pp.1177-1183 ,
Current evidence for the role of complement in the pathogenesis of Shiga toxin haemolytic uraemic syndrome, Pediatr Nephrol, vol.29, pp.1895-1902, 2014. ,
Interaction of Shiga toxin 2 with complement regulators of the factor H protein family, Mol Immunol, vol.58, pp.77-84, 2014. ,
Lateonset thrombocytic microangiopathy caused by cblC disease: association with a factor H mutation, Am J Kidney Dis, vol.45, pp.588-595, 2005. ,
CD46-associated atypical hemolytic uremic syndrome with uncommon course caused by cblC deficiency, Pediatr Nephrol, vol.25, pp.2547-2548, 2010. ,
Management of hemolytic uremic syndrome, Presse Med, vol.41, pp.115-135, 2012. ,
URL : https://hal.archives-ouvertes.fr/inserm-02149335
Factor H dysfunction in patients with atypical hemolytic uremic syndrome contributes to complement deposition on platelets and their activation, Blood, vol.111, pp.5307-5315, 2008. ,
Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome, J Am Soc Nephrol, vol.21, pp.2180-2187, 2010. ,
Complement factor H-related protein 1 deficiency and factor H antibodies in pediatric patients with atypical hemolytic uremic syndrome, Clin J Am Soc Nephrol, vol.8, pp.407-415, 2013. ,
Prompt plasma exchanges and immunosuppressive treatment improves the outcomes of anti-factor H autoantibodyassociated hemolytic uremic syndrome in children, Kidney Int, vol.85, pp.1151-1160, 2014. ,
Anti-factor H autoantibodyassociated haemolytic uremic syndrome: the earlier diagnosed and treated, the better, Kidney Int, vol.85, pp.1019-1022, 2014. ,
Complement factor h-antibodyassociated hemolytic uremic syndrome: pathogenesis, clinical presentation, and treatment, Semin Thromb Hemost, vol.40, pp.431-443, 2014. ,
Peripheral gangrene in children with atypical hemolytic uremic syndrome, Pediatrics, vol.131, pp.331-335, 2013. ,
Phenotypic expansion of DGKEassociated diseases, J Am Soc Nephrol, vol.25, pp.1408-1414, 2014. ,
Complement mutations in diacylglycerol kinase-?-associated atypical hemolytic uremic syndrome, Clin J Am Soc Nephrol, vol.9, pp.1611-1619, 2014. ,
Genetic and functional analyses of membrane cofactor protein (CD46) mutations in atypical hemolytic uremic syndrome, J Am Soc Nephrol, vol.17, pp.2017-2025, 2006. ,
European Working Party on Complement Genetics in Renal Diseases (2013) Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype, J Am Soc Nephrol, vol.24, pp.475-486 ,
Comprehensive genetic analysis of complement and coagulation genes in atypical hemolytic uremic syndrome, J Am Soc Nephrol, vol.25, pp.55-64, 2014. ,
Afshar-Kharghan V (2013) Partial ADAMTS13 deficiency in atypical hemolytic uremic syndrome, Blood, vol.22, pp.1487-1493 ,
Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome, Blood, vol.115, pp.379-387, 2010. ,
Determining the population frequency of the CFHR3/CFHR1 deletion at 1q32, PLoS One, vol.8, p.60352, 2013. ,
, Nat Genet, vol.45, pp.475-476, 2013.
Atypical hemolytic uremic syndrome in children: complement mutations and clinical characteristics, Pediatr Nephrol, vol.27, pp.1283-1291, 2012. ,
Biomarkers of the alternative pathway and terminal complement activity at presentation confirms the clinical diagnosis of aHUS and differentiates aHUS from TTP, Blood, vol.123, pp.3733-3738, 2014. ,
Dynamics of complement activation in aHUS and how to monitor eculizumab therapy, Blood, vol.124, pp.1715-1726, 2014. ,
Complement activation patterns in atypical hemolytic uremic syndrome during acute phase and in remission, Clin Exp Immunol, 2014. ,
Standardisation of the factor H autoantibody assay, Immunobiology, vol.219, pp.9-16, 2014. ,
Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome, Am J Transplant, vol.13, pp.663-675, 2013. ,
URL : https://hal.archives-ouvertes.fr/hal-00945715
French Study Group for Atypical HUS (2012) Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation, Am J Transplant, vol.12, pp.3337-3354 ,
Outcomes of renal transplant in patients with anticomplement factor H antibody-associated hemolytic uremic syndrome, Pediatr Transplant, vol.18, pp.134-139, 2014. ,
Post-transplant recurrence of atypical hemolytic uremic syndrome in a patient with thrombomodulin mutation, Pediatr Transplant, vol.17, pp.177-181, 2013. ,
Liver-kidney transplantation to cure atypical hemolytic uremic syndrome, J Am Soc Nephrol, vol.20, pp.940-949, 2009. ,
, Soliris (eculizumab): EU summary of product characteristics, European Medicines Agency
, Soliris_ (eculizumab): US prescribing information, Alexion Pharmaceuticals Inc, vol.4, 2014.
Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome: 2-year results from extensions of phase 2 studies, Kidney Int, 2015. ,
Eculizumab efficacy in aHUS patients with progressing TMA, with or without prior renal transplant, 2013. ,
, Am J Transplant, vol.13, pp.278-279
Eculizumab inhibits thrombotic microangiopathy and improves renal function in pediatric atypical hemolytic uremic syndrome patients, 2013. ,
, J Am Soc Nephrol, vol.24, pp.821-822
Eculizumab inhibits thrombotic microangiopathy, and improves renal function in adult atypical hemolytic uremic syndrome patients: 1-Year Update, 2014. ,
, J Am Soc Nephrol, vol.25, p.751
Safety and efficacy of eculizumab in adult aHUS patients, with or without a history of renal transplant, 2014. ,
, J Am Soc Nephrol, vol.25, p.754
A systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS), BMJ Open, vol.3, p.3573, 2013. ,
Long-term eculizumab improves clinical outcomes in atypical hemolytic uremic syndrome, Pediatr Nephrol, vol.27, pp.2323-2326, 2012. ,
Eculizumab therapy in a child with hemolytic uremic syndrome and CFI mutation, Pediatr Nephrol, vol.27, pp.2327-2331, 2012. ,
Preservation of renal function in atypical hemolytic uremic syndrome by eculizumab: a case report, Pediatrics, vol.130, pp.1385-1388, 2012. ,
Neonatal onset atypical hemolytic uremic syndrome successfully treated with eculizumab, Pediatr Nephrol, vol.28, pp.155-158, 2013. ,
Neurologic involvement in atypical hemolytic uremic syndrome and successful treatment with eculizumab, Pediatr Nephrol, vol.28, pp.827-830, 2013. ,
Eculizumab therapy for atypical haemolytic uraemic syndrome due to a gain-of-function mutation of complement factor B, Pediatr Nephrol, vol.28, pp.1315-1318, 2013. ,
Eculizumab for the treatment of atypical hemolytic uremic syndrome: case report and revision of the literature, J Bras Nefrol, vol.35, pp.237-241, 2013. ,
Eculizumab in atypical haemolytic uraemic syndrome with severe cardiac and neurological involvement, Pediatr Nephrol, vol.29, pp.1103-1106, 2013. ,
Eculizumab as first-line therapy for atypical hemolytic uremic syndrome, Pediatrics, vol.133, pp.1759-1763, 2014. ,
Eculizumab in neonatal hemolytic uremic syndrome with homozygous factor H deficiency, Pediatr Nephrol, vol.29, pp.2415-2419, 2014. ,
Insights from the use in clinical practice of eculizumab in adult patients with atypical hemolytic uremic syndrome affecting the native kidneys: an analysis of 19 cases, Am J Kidney Dis, vol.63, pp.40-48, 2014. ,
URL : https://hal.archives-ouvertes.fr/inserm-02162259
Clinical grand rounds: atypical hemolytic uremic syndrome, Am J Nephrol, vol.35, pp.394-394, 2012. ,
Eculizumab for the treatment of two recurrences of atypical hemolytic uremic syndrome in a kidney allograft, Transpl Int, vol.25, pp.93-95, 2012. ,
Successful long-term treatment of TMA with eculizumab in a transplanted patient with atypical hemolytic uremic syndrome due to MCP mutation, Transplantation, vol.96, pp.74-76, 2013. ,
Targeted strategies in the prevention and management of atypical HUS recurrence after kidney transplantation, Transplant Rev (Orlando), vol.27, pp.117-125, 2013. ,
Tailored eculizumab therapy in the management of complement factor H-mediated atypical hemolytic uremic syndrome in an adult kidney transplant recipient: a case report, Transplant Proc, vol.44, pp.3037-3040, 2012. ,
Anti-C5 as prophylactic therapy in atypical hemolytic uremic syndrome in living-related kidney transplantation, Transplantation, vol.96, pp.26-29, 2013. ,
Eculizumab long-term therapy for pediatric renal transplant in aHUS with CFH/CFHR1 hybrid gene, Pediatr Nephrol, vol.29, pp.149-153, 2014. ,
Eculizumab in an anephric patient with atypical haemolytic uraemic syndrome and advanced vascular lesions, Nephrol Dial Transplant, vol.28, pp.2899-2907, 2013. ,
Complement. First of two parts, N Engl J Med, vol.344, pp.1058-1066, 2001. ,
Immunogenicity and safety of a CRM-conjugated meningococcal ACWY vaccine administered concomitantly with routine vaccines starting at 2 months of age, Hum Vaccin Immunother, vol.10, pp.280-289, 2013. ,
Safety of a quadrivalent meningococcal serogroups A, C, W and Y conjugate vaccine (MenACWY-CRM) administered with routine infant vaccinations: results of an open-label, randomized, phase 3b controlled study in healthy infants, Vaccine, vol.32, pp.965-972, 2014. ,
Immunogenicity of meningococcus C vaccination in a patient with atypical hemolytic uremic syndrome (aHUS) on eculizumab therapy, Pediatr Transplant, vol.16, pp.246-250, 2012. ,
Meningococcal sepsis complicating eculizumab treatment despite prior vaccination, Am J Transplant, vol.13, pp.819-820, 2013. ,
Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria, Br J Haematol, vol.162, pp.62-73, 2013. ,
Long-term remission of atypical HUS with anti-factor H antibodies after cyclophosphamide pulses, Pediatr Nephrol, vol.29, pp.75-83, 2014. ,
Successful treatment of DEAP-HUS with eculizumab, Pediatr Nephrol, vol.29, pp.841-851, 2014. ,
Eculizumab in anti-factor h antibodies associated with atypical hemolytic uremic syndrome, Pediatrics, vol.133, pp.1764-1768, 2014. ,
Atypical HUS due to factor H antibodies in an adult patient successfully treated with eculizumab, Ren Fail, vol.36, pp.1119-1121, 2014. ,
Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome, J Am Soc Nephrol, vol.18, pp.2392-2400, 2007. ,
URL : https://hal.archives-ouvertes.fr/inserm-00409786
Complement activation in thrombotic thrombocytopenic purpura, J Thromb Haemost, vol.10, pp.791-798, 2012. ,
STEC-HUS, atypical HUS and TTP are all diseases of complement activation, Nat Rev Nephrol, vol.8, pp.622-633, 2012. ,
Complement activation and mortality during an acute episode of thrombotic thrombocytopenic purpura, J Thromb Haemost, vol.11, pp.1925-1927, 2013. ,
Complement and cytokine response in acute Thrombotic Thrombocytopenic Purpura, Br J Haematol, vol.164, pp.858-856, 2014. ,
Complement activation associated with ADAMTS13 deficiency in human and murine thrombotic microangiopathy, J Immunol, vol.191, pp.2184-2193, 2013. ,
Eculizumab in the treatment of refractory idiopathic thrombotic thrombocytopenic purpura, Br J Haematol, vol.157, pp.772-774, 2012. ,
Use of eculizumab in the treatment of a case of refractory, ADAMTS13-deficient thrombotic thrombocytopenic purpura: additional data and clinical follow-up, Br J Haematol, vol.162, pp.558-559, 2013. ,
Cryptic activity of atypical hemolytic uremic syndrome and eculizumab treatment, Pediatrics, vol.133, pp.1769-1771, 2014. ,
Eculizumab in the treatment of atypical hemolytic uremic syndrome in infants, Am J Kidney Dis, vol.59, pp.707-710, 2012. ,
Skin involvement in atypical hemolytic uremic syndrome, Am J Kidney Dis, vol.63, pp.652-655, 2013. ,
Eculizumab safely reverses neurologic impairment and eliminates need for dialysis in severe atypical hemolytic uremic syndrome, Clin Pharmacol, vol.3, pp.5-12, 2011. ,
Profound neurological injury in a patient with atypical hemolytic uremic syndrome, Ann Hematol, vol.92, pp.557-558, 2013. ,
Eculizumab: effectiveness of a shortened dosing schedule in the treatment of atypical haemolytic uremic syndrome of unknown origin, Therapie, vol.68, pp.119-122, 2013. ,
Successful discontinuation of eculizumab therapy in a patient with aHUS, Ann Hematol, vol.93, pp.1423-1425, 2014. ,
Atypical haemolytic-uraemic syndrome due to heterozygous mutations of CFH/CFHR1-3 and complement factor H 479, Blood Transfus, vol.12, pp.111-113, 2014. ,
Non-atheromatous arterial stenoses in atypical haemolytic uraemic syndrome associated with complement dysregulation, Nephrol Dial Transplant, vol.25, pp.3421-3425, 2010. ,
Prevention of large-vessel stenoses in atypical hemolytic uremic syndrome associated with complement dysregulation, Pediatr Nephrol, vol.26, pp.155-157, 2011. ,
Macrovascular involvement in a child with atypical hemolytic uremic syndrome, Pediatr Nephrol, vol.29, pp.1273-1277, 2013. ,
Early treatment with eculizumab may be beneficial in atypical haemolytic uraemic syndrome, Clin Kidney J, vol.5, pp.1-3, 2012. ,
Eculizumab in atypical haemolytic-uraemic syndrome allows cessation of plasma exchange and dialysis, Clin Kidney J, vol.0, pp.1-3, 2012. ,
Renal recovery with eculizumab in atypical hemolytic uremic syndrome following prolonged dialysis, Clin Nephrol, vol.82, pp.326-331, 2013. ,
Cardiovascular complications in atypical haemolytic uraemic syndrome, Nat Rev Nephrol, vol.10, pp.174-180, 2014. ,
Genetic variants in C5 and poor response to eculizumab, N Engl J Med, vol.370, pp.632-639, 2014. ,
Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome, J Thromb Haemost, vol.12, pp.1440-1448, 2014. ,
Complement inhibitor eculizumab in atypical hemolytic uremic syndrome, Clin J Am Soc Nephrol, vol.4, pp.1312-1316, 2009. ,
New treatment options for atypical hemolytic uremic syndrome with the complement inhibitor eculizumab, Semin Thromb Hemost, vol.36, pp.669-672, 2010. ,
Relapse of aHUS after discontinuation of therapy with eculizumab in a patient with aHUS and factor H mutation, Ann Hematol, vol.92, pp.845-846, 2013. ,
Post-partum atypical haemolytic uraemic syndrome treated with eculizumab: terminal complement activity assessment in clinical practice, Clin Kidney J, vol.6, pp.243-244, 2013. ,
Eculizumab for the treatment of pregnancy-related atypical hemolytic uremic syndrome, Ann Hematol, vol.93, pp.1421-1422, 2014. ,
Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome: a report of 10 cases, Am J Kidney Dis, vol.64, pp.633-637, 2014. ,
Living kidney transplantation in adult patients with atypical haemolytic uraemic syndrome, Neth J Med, vol.71, pp.342-347, 2013. ,
Changing strategies for organ transplantation in atypical haemolytic uraemic syndrome: a tertiary case series, Pediatr Transplant, vol.17, pp.93-99, 2013. ,
Liver-kidney transplantation to cure atypical HUS: still an option post-eculizumab?, Pediatr Nephrol, vol.29, pp.329-332, 2014. ,
Anesthetic management of living donor liver transplantation for complement factor H deficiency hemolytic uremic syndrome: a case report, Korean J Anesthesiol, vol.66, pp.481-485, 2014. ,